High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

This large scale pharmacodynamic analysis of HDM demonstrates that high melphalan exposure is associated with improved survival, with an acceptable increase in transplant toxicity. These results suggest studies targeting a higher AUC are warranted in patients undergoing HDM and ASCT for myeloma.